Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Actinium Pharmaceuticals Inc

ATNM ✗ NOT COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.04

▲ +7.90%

Market Cap $32.70M · Vol 34.66K

Key Metrics

P/E Ratio

2.92

FWD: N/A

Market Cap

$32.70M

Micro Cap

Div Yield

N/A

EPS Growth

+22.32%

YoY

RSI (14)

69.50

Momentum

Beta

0.09

vs Market

52W High

$1.80

42.22% below

52W Low

$0.74

40.54% above

Volume

34.66K

Avg 19.49K

P/B

5.42

Price-to-book

ROE

N/A

Return on equity

Free Float

97.66%

Public shares

Shariah Compliance8 STANDARDS

✗ Actinium Pharmaceuticals Inc (ATNM) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ATNM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+30.42%

+16.19%

-18.75%

-6.31%

YTD

-23.53%

-36.97%

-83.95%

-83.54%

Financials & Valuation

TTM · Annual

Total Revenue	$90.00K
Net Income	$-33,887,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-40,274.44%
Net Profit Margin	-37,652.22%
ROE	N/A
ROA · ROIC	-52.67% · N/A

P/E Ratio	2.92
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	471.40
P/B	5.42
P/FCF	N/A
EPS Growth	+22.32%
Outstanding Shares	31.44M

Technical Indicators

50-Day SMA	$0.93
200-Day SMA	$1.18
RSI (14)	69.50
Beta	0.09
52-Week High	$1.80
52-Week Low	$0.74

Volume Today	34.66K
Avg Daily Volume (30D)	19.49K
Relative Volume	1.78x
Volatility (10D)	99.80
Volatility (30D)	76.23
Free Float	97.66%

Analyst Consensus

BUY

Current Price $1.04

Mean Target $4.00

52W Low$0.74 52W High$1.80

Current

Target

$0.74 $1.80

Current Analyst target

+284.62% upside potential · 3 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001SV3L17

ISINUS00507W2061

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.